MetaVia Q2 net loss widens on higher R&D spending
MTVA•DA-1726 clinical trial updates
MetaVia said it completed dose titration in the Phase 1 Part 3 study of DA-1726, with all active patients reaching the highest planned dose levels.
The company said it presented data showing up to 9.1% mean weight loss after eight weeks of DA-1726 treatment, which it said reinforced confidence in the drug's profile.
MetaVia expects topline data from the DA-1726 Phase 1 Part 3 study in Q4 2026.
Cash position and pipeline outlook
Cash and cash equivalents rose to $12.6 million, and MetaVia said it expects its cash position to fund operations through 2026.
The company also said it plans an End-of-Phase 2 FDA meeting for vanoglipel in H2 2026.
Q2 loss widens on higher R&D spending
MetaVia said its Q2 net loss widened year over year on higher research and development spending for DA-1726.
The company reported a Q2 net loss of $5.32 million and Q2 operating expenses of $5.39 million. MetaVia attributed the increased operating expenses to higher direct R&D costs for DA-1726 product development.
